Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with ...
COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor ...
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 ...
Sonnet BioTherapeutics Holdings, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to its modified form of Interleukin-18, ...
PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
IL-18 is a potent pro-inflammatory cytokine that plays a vital role in the body's defense against infections and regulates both the innate and acquired immune response. Understanding the balance ...
Unique approach targets IL-18 with a smaller, IL-18 fusion protein antagonist, with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies EVO301 has ...
Gilead Sciences Inc. has signed an agreement with Compugen Ltd. to exclusively license Compugen’s preclinical antibody program against IL-18 binding protein, including the COM-503 drug candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results